The 2020 NBA season is officially scheduled to resume next week. The 22 teams that traveled to Walt Disney World, Florida will begin playing their series of games that will ultimately crystallize in the 2020 Playoffs. The NBA’s 2019-20 Restart plan has been criticized by some, but the league believes it will be able to resume the campaign on time and get through a full postseason without any major issues.
One company will play an integral role in the success of the season, and that’s not the only big news that could send this stock higher.
“BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK) will provide COVID-19 testing oversight for the National Basketball Association’s players and referees, as well as team and league staff participating in the NBA’s season in Orlando.” The company stated in a press release.
Under the agreement with the NBA, BioReference will provide COVID-19 testing, which includes PCR diagnostics, rapid diagnostics and antibody testing.
And that’s not the only big news sending OPK stock higher. OPKO has accepted a CDC contract to provide commercial surge capacity testing for COVID-19 emergency response to the CDC. The four month contract started yesterday.
